Pre-hospital Antifibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)

每年约有2500名澳大利亚人死于重伤。早发性凝血缺陷会加剧出血，这种缺陷与高死亡率有关。在较不发达的创伤系统中，抗纤溶药物氨甲环酸已被证明可以降低因出血而导致的死亡率，但在发达的系统中，它作为先发制人的打击手段的有效性尚不清楚。在我们院前临床试验专业知识的基础上，我们将进行一项试验，以评估其对6个月死亡和残疾的影响。

About 2500 Australians die annually from severe injuries. Bleeding is exacerbated by early-onset clotting defects, which are associated with high mortality. The antifibrinolytic agent tranexamic acid has been shown to reduce mortality due to bleeding when given in hospital in less developed trauma systems, but its usefulness as a pre-emptive strike at the scene of injury in developed systems is unknown. Building on our prehospital clinical trials expertise, we will conduct a trial to assess its effect on 6-month death and disability.